Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Levocetirizine
Accession Number
DB06282
Type
Small Molecule
Groups
Approved
Description

Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.2,3,4 It is the R enantiomer of cetirizine.4 Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine.4

Levocetirizine was granted FDA approval in 1995.4

Structure
Thumb
Synonyms
  • 2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
  • Levocetirizina
  • Levocetirizine
Product Ingredients
IngredientUNIICASInChI Key
Levocetirizine dihydrochlorideSOD6A38AGA130018-87-0PGLIUCLTXOYQMV-GHVWMZMZSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Levocetirizine DihydrochlorideTablet, film coated5 mg/1OralWinthrop U.S.2007-08-092018-10-11Us
Levocetirizine DihydrochlorideSolution0.5 mg/1mLOralWinthrop U.S.2008-04-022018-10-11Us
XyzalSolution0.5 mg/1mLOralUcb Inc2008-04-022018-06-08Us
XyzalTablet, film coated5 mg/1OralUcb Inc2007-08-092019-01-19Us50474 0920 90 nlmimage10 0a47850c
XyzalTablet5 mg/1OralUCB Farchim S.A.2008-02-19Not applicableUs
XyzalSolution0.5 mg/1mLOralsanofi-aventis U.S. LLC2017-07-24Not applicableUs
XyzalSolution0.5 mg/1mLOralSanofi Aventis2008-04-022018-10-25Us
XyzalSolution0.5 mg/1mLOralPhysicians Total Care, Inc.2010-04-27Not applicableUs
XyzalTablet, film coated5 mg/1Oralsanofi-aventis U.S. LLC2017-07-24Not applicableUs
XyzalTablet, film coated5 mg/1OralSanofi Aventis2007-08-092018-10-25Us00024 5800 90 nlmimage10 4112a085
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Levocetirizine DihydrochlorideTablet5 mg/1OralRemedy Repack2015-04-292017-02-01Us
Levocetirizine DihydrochlorideTablet, film coated5 mg/1OralMacleods Pharmaceuticals Limited2016-01-11Not applicableUs
Levocetirizine DihydrochlorideTablet, film coated5 mg/1OralSun Pharma Global FZE2013-02-052017-10-31Us
Levocetirizine DihydrochlorideTablet, film coated5 mg/1OralNucare Pharmaceuticals,inc.2016-01-11Not applicableUs
Levocetirizine DihydrochlorideTablet, film coated5 mg/1OralAidarex Pharmaceuticals LLC2013-02-05Not applicableUs
Levocetirizine DihydrochlorideTablet5 mg/1OralProficient Rx LP2010-11-26Not applicableUs
Levocetirizine DihydrochlorideTablet5 mg/1OralCamber Pharmaceuticals, Inc.2012-06-29Not applicableUs
Levocetirizine DihydrochlorideTablet5 mg/1OralAvKARE, Inc.2017-06-16Not applicableUs
Levocetirizine DihydrochlorideTablet5 mg/1OralGlenmark Pharmaceuticals Inc., USA2011-02-25Not applicableUs
Levocetirizine DihydrochlorideTablet, film coated5 mg/1OralPreferreed Pharmaceuticals Inc.2018-07-17Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
24HR Allergy ReliefTablet, coated5 mg/1OralCardinal Health2018-03-12Not applicableUs
Allergy ReliefTablet, coated5 mg/1OralAmerisource Bergen Drug Corportaion2018-04-20Not applicableUs
Allergy ReliefTablet, coated5 mg/1OralAlbertsons Companies2018-06-30Not applicableUs
Allergy Relief 24HRTablet5 mg/1OralVitesse Pharma LLC2019-07-02Not applicableUs
Allergy Relief 24HRTablet5 mg/1OralVelocity Pharma Llc2019-07-02Not applicableUs
Childrens Xyzal AllergySolution0.5 mg/1mLOralChattem, Inc.2017-02-16Not applicableUs
Levocetirizine DihydrochlorideTablet, coated5 mg/1OralHEB2019-06-15Not applicableUs
Levocetirizine DihydrochlorideTablet, coated5 mg/1OralDr. Reddy's Laboratories Inc.2018-12-26Not applicableUs
Levocetirizine DihydrochlorideTablet, coated5 mg/1OralWalgreens2018-03-26Not applicableUs
Levocetirizine DihydrochlorideTablet, coated5 mg/1OralWAL-MART STORES INC2019-07-26Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AlloPAXLevocetirizine dihydrochloride (3 g/3g) + Loratadine (3 g/3g)KitTransdermalPharmaGenetico LLC2015-06-30Not applicableUs
Clobetasol Propionate 0.05% / Levocetirizine Dihydrochloride 2%Levocetirizine dihydrochloride (2 g/100g) + Clobetasol propionate (0.05 g/100g)ShampooTopicalSincerus Florida, LLC2019-05-17Not applicableUs
Hydrocortisone 2.5% / Levocetirizine Dihydrochloride 2%Levocetirizine dihydrochloride (2 g/100g) + Hydrocortisone (2.5 g/100g)CreamTopicalSincerus Florida, LLC2019-05-15Not applicableUs
Imiquimod 5% / Levocetirizine Dihydrochloride 1% / Niacinamide 2%Levocetirizine dihydrochloride (1 g/100g) + Imiquimod (5 g/100g) + Nicotinamide (2 g/100g)GelTopicalSincerus Florida, LLC2019-05-01Not applicableUs
Imiquimod 5% / Levocetirizine Dihydrochloride 1% / Tretinoin 0.05%Levocetirizine dihydrochloride (1 g/100g) + Imiquimod (5 g/100g) + Tretinoin (0.05 g/100g)GelTopicalSincerus Florida, LLC2019-05-01Not applicableUs
Levocetirizine Dihydrochloride 2% / Mupirocin 2% / Triamcinolone Acetonide 0.025%Levocetirizine dihydrochloride (2 g/100g) + Mupirocin (2 g/100g) + Triamcinolone acetonide (0.025 g/100g)CreamTopicalSincerus Florida, LLC2019-05-15Not applicableUs
Nazirex Compounding KitLevocetirizine dihydrochloride (1 g/1g) + Loratadine (1 g/1g)KitTopicalAlvix Laboratories2015-03-182015-07-01Us
International/Other Brands
Xusal
Categories
UNII
6U5EA9RT2O
CAS number
130018-77-8
Weight
Average: 388.89
Monoisotopic: 388.1553704
Chemical Formula
C21H25ClN2O3
InChI Key
ZKLPARSLTMPFCP-OAQYLSRUSA-N
InChI
InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1
IUPAC Name
2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
SMILES
OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1

Pharmacology

Indication

Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria.4 It is also used over the counter for a variety of mild allergy symptoms.2

Associated Conditions
Pharmacodynamics

Levocetirizine is a second generation histamine H1 antagonist used to treat various allergic symptoms.2,3,4 It has a long duration of action as it is generally taken once daily, and a wide therapeutic window as animal studies show the maximal nonlethal dose is over 100x a normal dose.4 Patients are cautioned to avoid tasks that require complete alertness, avoid alertness, and use caution in patients with factors predisposing urinary retention.4

Mechanism of action

Levocetirizine selectively inhibits histamine H1 receptors.4 This action prevents histamine from activating this receptor and causing effects like smooth muscle contraction, increased permeability of vascular endothelium, histidine uptake in basophils, stimulation of cough receptors, and stimulation of flare responses in the nervous system.3

TargetActionsOrganism
AHistamine H1 receptor
antagonist
inhibitor
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Following a 5mg oral dose of levocetirizine, a Cmax of 0.27±0.04µg/mL with a Tmax of 0.75±0.50h.1 The AUC of levocetirizine is 2.31±0.50µg*h/mL.1 Taking levocetirizine with food does not affect the AUC but delays Tmax by 1.25 hours and lowers Cmax by 36%.4

Volume of distribution

The volume of distribution of levocetirizine is 0.33±0.02L/kg.1

Protein binding

Plasma protein binding of levocetirizine was on average 96.1% 1 hour post dose and 91.9% 6 hours post dose.1

Metabolism

Levocetirizine is poorly metabolized with 85.8% of an oral dose being excreted as the unchanged drug.1 Levocetirizine can be metabolized to a dihydrodiol (M2), an N-oxide (M3), a hydroxymethoxy derivative (M4), a hydroxy derivative (M5), an O-dealkylated derivative (M6), a taurine conjugate (M8), and an N-dealkylated and aromatic hydroxylated derivative (M9).1 The M5 metabolite can be glucuronidated to form the M1 metabolite and the M9 metabolite can form 4-chloro-4'-hydroxybenzhydryl mercapturates (M10a and M10b).1

Route of elimination

168 hours post dose an average of 85.4% of a radiolabeled dose was recovered with an average of 80.8% in the urine and 9.5% in the feces.1 In the urine, 77% of the dose was recovered as unchanged drug, 0.5% as the M8 and M9 metabolites, 0.4% as the M10a metabolite, 0.4% as the M10b metabolite, 0.3% as the M3 metabolite, 0.3% as the M4 and M5 metabolite, 0.2% as the M2 metabolite, and 0.1% as the M1 metabolite.1 In the feces, 9.0% of the dose was recovered as unchanged drug, 1.0% as the M4 and M5 metabolite, and 0.1% as the M1 metabolite.1

Half life

The average half life of levocetirizine is 7.05±1.54 hours.1

Clearance

The average clearance of levocetirizine is 0.57±0.18mL/min/kg.1

Toxicity

Patients experiencing an overdose may present with drowsiness.4 Children may become agitated and restless before drowsiness.4 Patients should be treated with supportive measures.4 Dialysis will not assist in removing the drug from the body.4

The maximal nonlethal dose in mice and rats is 240mg/kg.4

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Levocetirizine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Levocetirizine.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Levocetirizine.
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Levocetirizine.
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Levocetirizine.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Levocetirizine.
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Levocetirizine.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Levocetirizine.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Levocetirizine.
5-androstenedioneThe metabolism of Levocetirizine can be decreased when combined with 5-androstenedione.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with 5-methoxy-N,N-dimethyltryptamine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Benedetti MS, Plisnier M, Kaise J, Maier L, Baltes E, Arendt C, McCracken N: Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol. 2001 Oct;57(8):571-82. [PubMed:11758635]
  2. Mosges R, Konig V, Koberlein J: The effectiveness of levocetirizine in comparison with loratadine in treatment of allergic rhinitis--a meta-analysis. Allergol Int. 2011 Dec;60(4):541-6. doi: 10.2332/allergolint.10-OA-0300. Epub 2011 Sep 25. [PubMed:21918368]
  3. Desager JP, Horsmans Y: Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. Clin Pharmacokinet. 1995 May;28(5):419-32. doi: 10.2165/00003088-199528050-00006. [PubMed:7614779]
  4. FDA Approved Drug Products: Levocetirizine Dihydrochloride Tablets and Oral Solution [Link]
External Links
Human Metabolome Database
HMDB0240226
KEGG Drug
D07402
PubChem Compound
1549000
PubChem Substance
310264866
ChemSpider
1266001
BindingDB
85030
ChEBI
94559
ChEMBL
CHEMBL1201191
HET
LCR
Drugs.com
Drugs.com Drug Page
Wikipedia
Levocetirizine
ATC Codes
R06AE09 — Levocetirizine
PDB Entries
5dqf
FDA label
Download (167 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableRhinitis, Allergic, Perennial and Seasonal1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedPreventionSkin Inflammation1
1CompletedTreatmentAllergies1
1CompletedTreatmentFasting1
1CompletedTreatmentFasting State1
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentRhinitis2
2CompletedNot AvailableAllergic Rhinitis (AR)1
2CompletedTreatmentAllergic / Rhinitis / Rhinitis, Allergic, Seasonal / Seasonal1
2CompletedTreatmentCoughing1
2CompletedTreatmentNeoplasms, Colorectal1
3CompletedTreatmentAllergic Rhinitis (AR)2
3CompletedTreatmentAllergic Rhinitis (AR) / Chronic Urticaria2
3CompletedTreatmentAllergic / Perennial / Rhinitis1
3CompletedTreatmentAllergic / Rhinitis / Seasonal1
3CompletedTreatmentAtopic Dermatitis (AD)1
3CompletedTreatmentChronic Spontaneous Urticaria1
3CompletedTreatmentDermatitis, Eczematous / Skin Inflammation1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentRhinitis1
3CompletedTreatmentRhinitis, Allergic, Seasonal2
3CompletedTreatmentUrticarias2
3CompletedTreatmentVasomotor Rhinitis1
3RecruitingTreatmentAngiœdema / Urticarias1
3TerminatedTreatmentAsthma Bronchial1
4CompletedNot AvailableAnti-allergic Agents1
4CompletedNot AvailableRhinitis, Allergic, Perennial1
4CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedTreatmentAllergic Rhinitis (AR)5
4CompletedTreatmentAllergic / Perennial / Rhinitis1
4CompletedTreatmentAtopic Dermatitis (AD) / Pruritus1
4CompletedTreatmentChronic Idiopathic Urticaria1
4CompletedTreatmentChronic Urticaria1
4CompletedTreatmentHypersensitivity1
4CompletedTreatmentPerennial Allergic Rhinitis (PAR)2
4CompletedTreatmentRhinitis, Allergic, Perennial1
4CompletedTreatmentRhinitis, Allergic, Seasonal2
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)2
4Enrolling by InvitationTreatmentDeficiency, Vitamin D / Urticarias1
4Not Yet RecruitingTreatmentChronic Spontaneous Urticaria1
4Unknown StatusTreatmentChronic Idiopathic Urticaria / Urticarias1
4Unknown StatusTreatmentPerennial Allergic Rhinitis (PAR)1
Not AvailableCompletedNot AvailableRhinitis, Allergic, Perennial and Seasonal1
Not AvailableCompletedTreatmentAllergic Rhinitis (AR)1
Not AvailableCompletedTreatmentRhinitis, Allergic, Seasonal1
Not AvailableTerminatedNot AvailableRhinitis / Urticarias1
Not AvailableUnknown StatusDiagnosticAsthma Bronchial / Asthma, Allergic / Non-allergic Asthma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
KitTransdermal
ShampooTopical
GelTopical
SolutionOral2.5 mg/5mL
Tablet, coatedOral5 mg/1
Tablet, film coatedOral5 mg/1
CreamTopical
KitTopical
SolutionOral0.5 mg/1mL
TabletOral5 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5698558No1997-12-162013-03-24Us
US8633194No2014-01-212027-10-16Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)205-208http://www.chemspider.com/Chemical-Structure.1266001.html
boiling point (°C)542.1http://www.chemspider.com/Chemical-Structure.1266001.html
Predicted Properties
PropertyValueSource
Water Solubility0.0658 mg/mLALOGPS
logP2.98ALOGPS
logP0.87ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)3.59ChemAxon
pKa (Strongest Basic)7.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.01 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity106.87 m3·mol-1ChemAxon
Polarizability41.93 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0019000000-e24b60aef9a19aa0ca89
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0090000000-4fbbabe7bf3d0ad4cab5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0190000000-8783499dc5c2d31a3f7a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0uxr-0790000000-4efaf73700a535eb98e9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0920000000-f952b59e46cde6d2cfac
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0492000000-90537be4971a327c0fb1

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
N-alkylpiperazines / Chlorobenzenes / Aralkylamines / Aryl chlorides / Trialkylamines / Amino acids / Monocarboxylic acids and derivatives / Dialkyl ethers / Carboxylic acids / Azacyclic compounds
show 5 more
Substituents
Diphenylmethane / Chlorobenzene / Halobenzene / N-alkylpiperazine / Aralkylamine / Aryl halide / 1,4-diazinane / Aryl chloride / Piperazine / Amino acid
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
Inhibitor
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Ferrer M: Pharmacokinetic evaluation of levocetirizine. Expert Opin Drug Metab Toxicol. 2011 Aug;7(8):1035-47. doi: 10.1517/17425255.2011.590131. Epub 2011 Jun 4. [PubMed:21639816]
  2. Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. [PubMed:18336052]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. FDA Approved Drug Products: Levocetirizine Dihydrochloride Tablets and Oral Solution [Link]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Liu X, Du Y, Sun W, Kou J, Yu B: Study on the interaction of levocetirizine dihydrochloride with human serum albumin by molecular spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2009 Dec;74(5):1189-96. doi: 10.1016/j.saa.2009.09.033. Epub 2009 Oct 4. [PubMed:19857990]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Noguchi S, Nishimura T, Mukaida S, Benet LZ, Nakashima E, Tomi M: Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 Sep;106(9):2895-2898. doi: 10.1016/j.xphs.2017.03.026. Epub 2017 Apr 4. [PubMed:28385546]

Drug created on March 19, 2008 10:21 / Updated on September 02, 2019 21:47